NYSEARCA:BVX - NYSE Arca - US10211F1003
NYSEARCA:BVX (12/31/2018, 8:04:02 PM)
6.48
+0.07 (+1.09%)
The current stock price of BVX is 6.48 null. In the past month the price decreased by -6.76%. In the past year, price increased by 151.16%.
Bovie Medical Corporation, formerly An-Con Genetics Inc., is engaged in the manufacturing and marketing of a diverse line of medical devicesand advanced coating technologies.
BOVIE MEDICAL CORP
5115 Ulmerton Road
Clearwater FL 33760
CEO: Charles D. Goodwin II
Phone: 727-384-2323
The current stock price of BVX is 6.48 null. The price increased by 1.09% in the last trading session.
The exchange symbol of BOVIE MEDICAL CORP is BVX and it is listed on the NYSE Arca exchange.
BVX stock is listed on the NYSE Arca exchange.
BOVIE MEDICAL CORP (BVX) has a market capitalization of 215.14M null. This makes BVX a Micro Cap stock.
BOVIE MEDICAL CORP (BVX) has a support level at 6.47 and a resistance level at 6.49. Check the full technical report for a detailed analysis of BVX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BVX does not pay a dividend.
BOVIE MEDICAL CORP (BVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
ChartMill assigns a technical rating of 6 / 10 to BVX. When comparing the yearly performance of all stocks, BVX is one of the better performing stocks in the market, outperforming 98.82% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to BVX. Both the health and profitability get an excellent rating, making BVX a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months BVX reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 55.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 184.4% | ||
ROA | 59.36% | ||
ROE | 73.54% | ||
Debt/Equity | 0 |